A Cannabis-Tolerance Review Found Limited Evidence for Voluntary Compensation Across Functions
A 2020 review contrasted pharmacodynamic adaptation with the idea that users can deliberately overcome cannabis-related deficits. It characterized evidence for voluntary compensation as weak and limited to selected functions.
The models explain different possibilities
A pharmacodynamic model concerns changes in biological responsiveness after repeated exposure. A behavioral model concerns how a person performs or compensates during exposure. The two should not be treated as interchangeable explanations for a smaller observed effect.
One preserved function does not establish complete control
The review emphasized limited evidence of deliberate control over a limited set of functions. Success on one practiced task cannot establish equivalent control over unfamiliar, divided-attention or complex situations. A general claim of being able to handle the drug needs more than an isolated performance example.
The necessary exposure history remained uncertain
The authors identified gaps in the frequency, dose and duration needed to acquire, maintain or reduce tolerance. A category such as regular user cannot therefore supply a validated personal tolerance level on its own.
Interpreting the evidence
This synthesis supports distinguishing biological adaptation from claimed compensation and naming the function tested. It does not establish that every chronic user is unimpaired or that a person's confidence proves restored ability.
Related reading: interpreting cannabis tolerance claims.
Research reference
Ramaekers JG; Mason NL; Theunissen EL (2020). Blunted highs: Pharmacodynamic and behavioral models of cannabis tolerance. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. doi:10.1016/j.euroneuro.2020.01.006.
This analysis draws on the supplied review abstract.
